Biogen wins protection for MS drug Tecfidera in Europe

LONDON Fri Nov 22, 2013 8:41am EST

LONDON Nov 22 (Reuters) - Biogen Idec has won regulatory protection for its top-selling multiple sclerosis drug Tecfidera in Europe, paving the way for its launch in markets that could account for a large proportion of future sales.

The European Medicines Agency said on Friday it had granted the oral medicine a "new active substance" (NAS) designation, securing Biogen 10 years protection through data exclusivity that will stop generic firms from launching copycat versions.

In March, Tecfidera was approved in the United States and also recommended for approval in Europe - but its EU launch has been delayed, pending a resolution of uncertainty over data protection.

Without this protection, Biogen would have to rely on relatively weak patents relating the drug's use, which analysts believe might not prevent generic rivals launching cheaper copies in key markets like Germany.

Tecfidera competes with Novartis' Gilenya and Sanofi's Aubagio, two other oral therapies for multiple sclerosis (MS).

Oral treatments have proved a popular alternative to traditional drug injections for the debilitating neurological disorder and Tecfidera sales have exceeded market expectations, reaching $286 million in the third quarter.

Annual sales are expected to reach $4.55 billion by 2018, according to consensus forecasts compiled by Thomson Reuters Pharma, with 36 percent of that coming from Europe and other non-U.S. markets.

Tecfidera was launched at a U.S. price of $54,900 per patient a year. However, a Biogen executive said at a broker conference last week that Tecfidera might be priced at around half this level in Europe.

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (1)
Inquirya wrote:
Why find a cure when the treatments are much more lucrative? $54K per patient in the US, and $28K for Europeans… same drug? same company?

Feeling ripped off yet, MS patients?

Nov 22, 2013 6:28pm EST  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.